{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:19:47Z","timestamp":1790882387416,"version":"4.1.0"},"reference-count":133,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1517\/13543784.15.8.947","type":"journal-article","created":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T09:52:58Z","timestamp":1153475578000},"page":"947-961","source":"Crossref","is-referenced-by-count":19,"title":["Novel gene-directed enzyme prodrug therapies against prostate cancer"],"prefix":"10.1517","volume":"15","author":[{"given":"Pamela J","family":"Russell","sequence":"first","affiliation":[{"name":"Oncology Research Centre, Prince of Wales Hospital Sydney, Level 2, Clinical Sciences Building, Barker Street, Randwick, NSW 2031, Australia."},{"name":"Oncology Research Centre, Department of Clinical Medicine, University of New South Wales, Level 2, Clinical Sciences Building, Prince of Wales Hospital, Barker Street, Randwick, NSW 2031, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparajita","family":"Khatri","sequence":"additional","affiliation":[{"name":"Oncology Research Centre, Department of Clinical Medicine, University of New South Wales, Level 2, Clinical Sciences Building, Prince of Wales Hospital, Barker Street, Randwick, NSW 2031, Australia"},{"name":"Oncology Research Centre, Prince of Wales Hospital Sydney, Level 2, Clinical Sciences Building, Prince of Wales Hospital, Barker Street, Randwick, NSW 2031, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2006,7,21]]},"reference":[{"key":"e_1_3_1_3_1","first-page":"284","volume":"18","author":"RYAN","year":"2005","unstructured":"RYAN CJ, SMALL EJ: Prostate cancer update: 2005. Curr. Opin. Oncol. (2005) 18:284-288.","journal-title":"Curr. Opin."},{"key":"e_1_3_1_4_1","first-page":"257","volume":"17","author":"RYAN","year":"2005","unstructured":"RYAN CJ, SMALL EJ: Progress in detection and treatment of prostate cancer. Curr. Opin. Oncol. (2005) 17:257-260.","journal-title":"Curr."},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cr\/52.1.23"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931215)72:12 <3888::AID-CNCR2820721726>3.0.CO;2-B"},{"key":"e_1_3_1_7_1","first-page":"1737","volume":"11","author":"WALCZAK","year":"2002","unstructured":"WALCZAK HR, CARDUCCI MA: Pharmacological treatments for prostate cancer. Expert Opin. Investig. Drugs (2002) 11(12):1737-1748.","journal-title":"Expert"},{"key":"e_1_3_1_8_1","first-page":"2506","volume":"17","author":"KANTOFF","year":"1999","unstructured":"KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer. Results of the Cancer and Leukemia Group B9182 study. J. Clin. Oncol. (1999) 17(8):2506-2513.","journal-title":"J."},{"key":"e_1_3_1_9_1","first-page":"1756","volume":"14","author":"TANNOCK","year":"1996","unstructured":"TANNOCK IF, OSOBA D, STOCKLER MR et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. (1996) 14:1756-1764.","journal-title":"J."},{"key":"e_1_3_1_10_1","first-page":"1273","volume":"12","author":"BEER","year":"2001","unstructured":"BEER TM, PIERCE WC, LOWE BA, HENNER WD: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann. Oncol. (2001) 12(9):1273-1279.","journal-title":"Ann."},{"key":"e_1_3_1_11_1","first-page":"1502","volume":"351","author":"TANNOCK","year":"2004","unstructured":"TANNOCK IF, DE WIT R, BERRY WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. (2004) 351:1502-1512.","journal-title":"N."},{"key":"e_1_3_1_12_1","first-page":"37","volume":"31","author":"KALIBEROV","year":"2006","unstructured":"KALIBEROV SA, BUCHSBAUM DJ: Gene delivery and gene therapy of prostate cancer. Expert Opin. Drug Deliv. (2006) 31(1):37-51.","journal-title":"Expert"},{"key":"e_1_3_1_13_1","first-page":"497","volume":"15","author":"FERRER","year":"2001","unstructured":"FERRER FA, RODRIGUEZ F: Prostate cancer gene therapy. Hematol. Oncol. Clin. North Am. (2001) 15:497-508.","journal-title":"Hematol. Oncol."},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01525-6"},{"key":"e_1_3_1_15_1","first-page":"187","volume":"4","author":"YAMANAKA","year":"2005","unstructured":"YAMANAKA K, GLEAVE ME, HARA I, MURAMAKI M, MIYAKE H: Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol. Cancer Ther. (2005) 4(2):187-195.","journal-title":"Mol."},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0829"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10138"},{"key":"e_1_3_1_18_1","first-page":"105","volume":"7","author":"SIMPSON","year":"2004","unstructured":"SIMPSON E: Immunotherapy and gene therapy. IDrugs (2004) 7(2):105-108.","journal-title":"IDrugs"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700896"},{"key":"e_1_3_1_20_1","first-page":"193","volume":"7","author":"LUPOLD","year":"2005","unstructured":"LUPOLD SE, RODRIGUEZ R: Adenoviral gene therapy, radiation, and prostate cancer. Rev. Urol. (2005) 7(4):193-202.","journal-title":"Rev."},{"key":"e_1_3_1_21_1","first-page":"522","volume":"5","author":"NOWROOZI","year":"1998","unstructured":"NOWROOZI MR, PISTERS LL: The current status of gene therapy for prostate cancer. Cancer Control (1998) 5(6):522-531.","journal-title":"Cancer"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.293"},{"key":"e_1_3_1_23_1","first-page":"8039","volume":"88","author":"HUBER","year":"1991","unstructured":"HUBER BA, RICHARDS CA, KREITSKY TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma : an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA (1991) 88:8039-8043.","journal-title":"Proc."},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20010"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700885"},{"key":"e_1_3_1_26_1","first-page":"649","volume":"10","author":"PUHLMANN","year":"1999","unstructured":"PUHLMANN M, GNANT M, BROWN CK, ALEXANDER HR, BARTLETT DL: Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum. Gene Ther. (1999) 10:649-657.","journal-title":"Hum."},{"key":"e_1_3_1_27_1","first-page":"339","volume":"16","author":"BHARARA","year":"2005","unstructured":"BHARARA S, SORSCHER EJ, GILLESPIE GY et al.: Antibiotic-mediated chemoprotection enhances adaptation of E. coli PN for herpes simplex virus-based glioma therapy. Hum. Gene Ther. (2005) 16(3):339-347.","journal-title":"Hum."},{"key":"e_1_3_1_28_1","first-page":"1343","volume":"6","author":"WANG","year":"2004","unstructured":"WANG XY, MARTINIELLO-WILKS R, SHAW JM et al.: Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther. (2004) 6(12):1343-1357.","journal-title":"Gene Ther."},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301698"},{"key":"e_1_3_1_30_1","first-page":"255","volume":"2","author":"HELLER","year":"2005","unstructured":"HELLER LC, UGEN K, HELLER R: Electroporation for targeted gene transfer. Expert Opin. Drug Deliv. (2005) 2(2):255-268.","journal-title":"Expert"},{"key":"e_1_3_1_31_1","first-page":"15","volume":"15","author":"KOSTARELOS","year":"2005","unstructured":"KOSTARELOS K, EMFIETZOGLOU D, PAPAKOSTAS A, YANG WH, BALLANGRUD AM, SGOURAS G: Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids. J. Liposome Res. (2005) 15(1-2):15-27.","journal-title":"J."},{"key":"e_1_3_1_32_1","first-page":"634","volume":"1","author":"BISANZ","year":"2005","unstructured":"BISANZ K, YU J, EDLUND M et al.: Targeting ECM\u2013integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imging model. Mol. Ther. (2005) 1(4):634-643.","journal-title":"Mol."},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2736(98)00248-X"},{"key":"e_1_3_1_34_1","first-page":"243","volume":"2","author":"HATTORI","year":"2005","unstructured":"HATTORI Y, MAITANI Y: Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr. Drug Deliv. (2005) 2(3):243-252.","journal-title":"Curr."},{"key":"e_1_3_1_35_1","first-page":"16028","volume":"101","author":"ANDERSON","year":"2004","unstructured":"ANDERSON DG, PENG W, AKINC A et al.: A polymer library approach to suicide gene therapy for cancer. Proc. Natl. Acad. Sci. USA (2004) 101(45):16028-16033.","journal-title":"Proc."},{"key":"e_1_3_1_36_1","first-page":"299","volume":"6","author":"GLOVER","year":"2005","unstructured":"GLOVER DJ, LIPPS HJ, JANS DA: Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. (2005) 6(4):299-310.","journal-title":"Nat."},{"key":"e_1_3_1_37_1","first-page":"348","volume":"97","author":"KANEDA","year":"2006","unstructured":"KANEDA Y, TABATA Y: Non-viral vectors for cancer therapy. Cancer Sci. (2006) 97(5):348-354.","journal-title":"Cancer"},{"key":"e_1_3_1_38_1","first-page":"177","volume":"2","author":"PFEIFER","year":"2001","unstructured":"PFEIFER A, VERMA IM: Gene therapy: promises and problems. Ann. Rev. Genomics Hum. Genet. (2001) 2:177-211.","journal-title":"Ann."},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043453252"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0090115"},{"key":"e_1_3_1_41_1","first-page":"473","volume":"1","author":"BERGES","year":"1995","unstructured":"BERGES RR, VUKANOVIC J, EPSTEIN J et al.: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. (1995) 1(5):473-480.","journal-title":"Clin."},{"key":"e_1_3_1_42_1","first-page":"1239","volume":"10","author":"HERMAN","year":"1999","unstructured":"HERMAN JR, ADLER HL, AGUILA-CORDOVA E et al.: In situ gene therapy for adenocarcinoma of the prostate: a Phase I clinical trial. Hum. Gene Ther. (1999) 10:1239-1249.","journal-title":"Hum."},{"key":"e_1_3_1_43_1","first-page":"4968","volume":"62","author":"FREYTAG","year":"2002","unstructured":"FREYTAG SO, KHIL M, STRICKER H et al.: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. (2002) 62(17):4968-4976.","journal-title":"Cancer Res"},{"key":"e_1_3_1_44_1","first-page":"7497","volume":"63","author":"FREYTAG","year":"2003","unstructured":"FREYTAG SO, STRICKER H, PEGG J et al.: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res. (2003) 63(21):7497-7506.","journal-title":"Cancer Res"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1317968"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)22001-5"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700004"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301669"},{"key":"e_1_3_1_49_1","first-page":"2075","volume":"3","author":"LOCKETT","year":"1997","unstructured":"LOCKETT LJ, MOLLOY PL, RUSSELL PJ, BOTH GW: Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin. Cancer Res. (1997) 3(11):2075-2080.","journal-title":"Clin."},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301549"},{"key":"e_1_3_1_51_1","first-page":"1287","volume":"334","author":"LI","year":"2005","unstructured":"LI HW, LI J, HELM GA, PAN D: Highly specific expression of luciferase gene in lungs of na\u00efve nude mice directed by prostate-specific antigen promoter. Biochem. Biophys. Res. Commun. (2005) 334(4):1287-1291.","journal-title":"Biochem."},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1006\/geno.2000.6446"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01256-0"},{"key":"e_1_3_1_54_1","first-page":"415","volume":"6","author":"LEE","year":"2002","unstructured":"LEE SJ, KIM HS, YU R et al.: Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol. Ther. (2002) 6(3):415-421.","journal-title":"Mol."},{"key":"e_1_3_1_55_1","first-page":"230","volume":"8","author":"GREENBERG","year":"1994","unstructured":"GREENBERG N, DE MAYO F, SHEPPARD PC et al.: The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. (1994) 8:230-239.","journal-title":"Mol."},{"key":"e_1_3_1_56_1","first-page":"31763","volume":"269","author":"KASPER","year":"1994","unstructured":"KASPER S, RENNIE PS, BRUCHOVSKY N et al.: Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J. Biol. Chem. (1994) 269:31763-31769.","journal-title":"Biol."},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19980401)35:1<18::AID-PROS3>3.0.CO;2-D"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj20021816"},{"key":"e_1_3_1_59_1","first-page":"367","volume":"95","author":"IKEGAMI","year":"2004","unstructured":"IKEGAMI S, TADAKUMA T, ONO T et al.: Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter\/enhancer in a castrated mouse model of prostate cancer. Cancer Sci. (2004) 95(4):367-370.","journal-title":"Cancer"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301895"},{"key":"e_1_3_1_61_1","first-page":"4270","volume":"7","author":"PRAMUDJI","year":"2001","unstructured":"PRAMUDJI C, SHIMRA S, EBARA S et al.: in situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin. Cancer Res. (2001) 7(12):4270-4279.","journal-title":"Clin."},{"key":"e_1_3_1_62_1","first-page":"316","volume":"5","author":"EBARA","year":"2002","unstructured":"EBARA S, SHIMURA S, NASU Y et al.: Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prostate Cancer Prost. Dis. (2002) 5(4):316-325.","journal-title":"Prostate"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700665"},{"key":"e_1_3_1_64_1","first-page":"231","volume":"118","author":"HSIEH","year":"2004","unstructured":"HSIEH CL, KUBO H, CHUNG LW: Gene therapy for prostate cancer bone metastasis. Gene therapy targeting bone metastasis. Cancer Treat. Res. (2004) 118:231-290.","journal-title":"Cancer"},{"key":"e_1_3_1_65_1","first-page":"2559","volume":"57","author":"RODRIGUEZ","year":"1997","unstructured":"RODRIGUEZ R, SCHUUR ER, LIM HY, HENDERSON GA, SIMONS JW, HENDERSON DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559-2563.","journal-title":"Cancer Res."},{"key":"e_1_3_1_66_1","first-page":"1574","volume":"14","author":"DOUGLAS","year":"1996","unstructured":"DOUGLAS JT, ROGERS BE, ROSENFELD ME, MICHAEL SI, FENG M, CURIEL DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. (1996) 14:1574-1578.","journal-title":"Nat."},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300941"},{"key":"e_1_3_1_68_1","first-page":"337","volume":"4","author":"EVERTS","year":"2004","unstructured":"EVERTS M, CURIEL DT: Transductional targeting of adenoviral cancer gene therapy. Curr. Gene Ther. (2004) 4(3):337-346.","journal-title":"Curr."},{"key":"e_1_3_1_69_1","first-page":"189","volume":"82","author":"BOTH","year":"2004","unstructured":"BOTH GW: Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector. Immunol. Cell Biol. (2004) 82(2):189-195.","journal-title":"Immunol."},{"key":"e_1_3_1_70_1","first-page":"685","volume":"6","author":"NICULESCU-DUVAZ","year":"1997","unstructured":"NICULESCU-DUVAZ I, SPRINGER CJ: Gene-directed enzyme prodrug therapy: a review of enzyme\/prodrug combinations. Expert Opin. Invest. Drugs (1997) 6(6):685-703.","journal-title":"Expert"},{"key":"e_1_3_1_71_1","first-page":"48","volume":"2003","author":"DENNY","year":"2003","unstructured":"DENNY WA: Prodrugs for gene-directed enzyme prodrug therapy (gene therapy). J. Biomed. Biotechnol. (2003) 2003(1):48-70.","journal-title":"J."},{"key":"e_1_3_1_72_1","first-page":"581","volume":"55","author":"CHEN","year":"1995","unstructured":"CHEN L, WAXMAN DJ: Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy\/cancer gene therapy strategy. Cancer Res. (1995) 55:581-589.","journal-title":"Cancer Res."},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2659-2663.2000"},{"key":"e_1_3_1_74_1","first-page":"669","volume":"72","author":"PATTERSON","year":"1999","unstructured":"PATTERSON AV, ZHANG H, MOGHADDAM A et al.: Increased sensitivity to the prodrug 5\u2032-deoxy-5-fluorodine and modulation of 5-fluoro-s-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer (1999) 72:669-675.","journal-title":"Br."},{"key":"e_1_3_1_75_1","first-page":"2343","volume":"56","author":"HAPKE","year":"1996","unstructured":"HAPKE DM, STEGMANN APA, MITCHELL BS: Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. (1996) 56:2343-2347.","journal-title":"Cancer Res"},{"key":"e_1_3_1_76_1","first-page":"447","volume":"148","author":"SHERWOOD","year":"1985","unstructured":"SHERWOOD RF, MELTON RG, ALWAN SM, HUGHES P: Purification and properties of carboxypeptidase G2 Pseudomonas spp. strain RS-16. Eur. J. Biochem. (1985) 148:447-453.","journal-title":"Eur."},{"key":"e_1_3_1_77_1","first-page":"22","volume":"187","author":"GRECO","year":"2001","unstructured":"GRECO O, DACHS GU: Gene directed enzyme\/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol. (2001) 187(1):22-36.","journal-title":"J."},{"key":"e_1_3_1_78_1","first-page":"123","volume":"93","author":"SPOONER","year":"2001","unstructured":"SPOONER RA, MAYCROFT KA, PATERSON H, FRIEDLOS F, SPRINGER CJ, MARAIS R: Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy. Int. J. Cancer (2001) 93(1):123-130.","journal-title":"Int."},{"key":"e_1_3_1_79_1","first-page":"777","volume":"8","author":"PERRY","year":"1999","unstructured":"PERRY MJ, TODRYK SM, DALGLEISH AG: The role of herpes simplex virus thymidine kinase in the treatment of solid tumours. Expert Opin. Investig. Drugs (1999) 8(6):777-785.","journal-title":"Expert"},{"key":"e_1_3_1_80_1","first-page":"224","volume":"12","author":"GOLUMBEK","year":"1992","unstructured":"GOLUMBEK PT, HAMZEH FM, JAFFEE EM, LEVITSKY H, LIETMAN PS, PARDOLL DM: Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, non-immunogenic tumour cell vaccines. J. Immunother. (1992) 12:224-230.","journal-title":"J."},{"key":"e_1_3_1_81_1","first-page":"33","volume":"18","author":"ELION","year":"1980","unstructured":"ELION GB: The chemotherapeutic exploitation of virus-specific enzymes. Adv. Enzymes Reg. (1980) 18:33-66.","journal-title":"Adv."},{"key":"e_1_3_1_82_1","first-page":"11879","volume":"257","author":"ALLAUDEEN","year":"1982","unstructured":"ALLAUDEEN HS, DESCAMPS J, SEHGAL RK, FOX JJ: Selective inhibition of DNA replication in herpes simplex virus infected cells by I-(2\u2032-deoxy-s-fluoro-B-D-arabino furanosyl)-5-iodocytosine. J. Biol. Chem. (1982) 257:11879-11887.","journal-title":"J."},{"key":"e_1_3_1_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300966"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301834"},{"key":"e_1_3_1_85_1","first-page":"759","volume":"85","author":"CHEON","year":"2000","unstructured":"CHEON J, KIM HK, MOON DG, YOON DK, CHO JH, KOH SK: Adenovirus-mediated suicide-gene therapy using the herpes simlex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity. Br. J. Urol. (2000) 85(6):759-766.","journal-title":"Br."},{"key":"e_1_3_1_86_1","first-page":"1617","volume":"9","author":"MARTINIELLO-WILKS","year":"1998","unstructured":"MARTINIELLO-WILKS R, GARCIA-ARAGON J, DAJA MM et al.: In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-prodrug therapy systems delivered by identical adenoviral vectors. Hum. Gene Ther. (1998) 9(11):1617-1626.","journal-title":"Hum."},{"key":"e_1_3_1_87_1","first-page":"227","volume":"14","author":"KUBO","year":"2003","unstructured":"KUBO H, GARDNER TA, WADA Y et al.: Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. (2003) 14(3):227-241.","journal-title":"Hum."},{"key":"e_1_3_1_88_1","first-page":"1193","volume":"168","author":"PANTUCK","year":"2002","unstructured":"PANTUCK AJ, BERGER F, ZISMAN A et al.: CLI-SR39: a non-invasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. J. Urol. (2002) 168(3):1193-1198.","journal-title":"J."},{"key":"e_1_3_1_89_1","first-page":"825","volume":"60","author":"MALIK","year":"2004","unstructured":"MALIK N, LUTHRA SK, BURKE P et al.: Radiosynthesis of 4-((2-chloroethyl)(2-(11C)ethyl)amino)- phenoxycarbonyl-L-glutamic acid a half mustard prodrug as a potential probe for imaging antibody- and gene-directed enzyme prodrug therapy with positron emission tomography. Appl. Radiat. Isot. (2004) 60:825-834.","journal-title":"Appl."},{"key":"e_1_3_1_90_1","first-page":"2173","volume":"164","author":"ANELLO","year":"2000","unstructured":"ANELLO R, COHEN S, ATKINSON G, HALL SJ: Adenovirus mediated cytosine deaminase gene transduction and 5-flouorocytosine therapy sensitizes mouse prostate cancer cells to irradiation. J. Urol. (2000) 164:2173-2177.","journal-title":"J."},{"key":"e_1_3_1_91_1","first-page":"985","volume":"8","author":"CRYSTAL","year":"1997","unstructured":"CRYSTAL R, HIRSCHOWITZ E, LIEBERMAN M et al.: Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with oral administration of the prodrug 5-fluorocytosine. Hum. Gene Ther. (1997) 8:985-1001.","journal-title":"Hum."},{"key":"e_1_3_1_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1998.tb13205.x"},{"key":"e_1_3_1_93_1","first-page":"2403","volume":"36","author":"KOYAMA","year":"2000","unstructured":"KOYAMA F, SAWADA H, FUJII H et al.: Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur. J. Cancer (2000) 36:2403-2410.","journal-title":"Eur."},{"key":"e_1_3_1_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301557"},{"key":"e_1_3_1_95_1","first-page":"77","volume":"11","author":"ADACHI","year":"2000","unstructured":"ADACHI Y, TAMIYA T, ICHIKAWA T et al.: Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum. Gene Ther. (2000) 11:77-89.","journal-title":"Hum."},{"key":"e_1_3_1_96_1","first-page":"30","volume":"5","author":"MIYAGI","year":"2003","unstructured":"MIYAGI T, KOSHIDA K, HORI O et al.: Gene therapy for prostate cancer using the cytosine deaminase\/uracil phosphoribosyltransferase suicide system. J. Gene Med. (2003) 5:30-37.","journal-title":"J."},{"key":"e_1_3_1_97_1","first-page":"1926","volume":"58","author":"KANAI","year":"1998","unstructured":"KANAI F, KAWAKAMI T, HAMADA H et al.: Adenovirus-mediated transduction of Escherichia coli uracil hosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res. (1998) 58:1926-1951.","journal-title":"Cancer Res"},{"key":"e_1_3_1_98_1","first-page":"9821","volume":"96","author":"STEGMAN","year":"1999","unstructured":"STEGMAN LD, REHEMTULLA A, BEATTIE B et al.: Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. USA (1999) 96(17):9821-9836.","journal-title":"Proc."},{"key":"e_1_3_1_99_1","first-page":"1417","volume":"59","author":"KIEVIT","year":"1999","unstructured":"KIEVIT E, BERSHAD E, NG E et al.: Superiority of yeast over bacterial cytosine deaminase therapy in colon cancer xenografts. Cancer Res. (1999) 59(7):1417-1421.","journal-title":"Cancer Res"},{"key":"e_1_3_1_100_1","first-page":"3813","volume":"60","author":"ERBS","year":"2000","unstructured":"ERBS P, REGULIER E, KINTZ J et al.: In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase\/uracil phosphoribosyltransferase fusion gene. Cancer Res. (2000) 60:3813-3822.","journal-title":"Cancer Res"},{"key":"e_1_3_1_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0012"},{"key":"e_1_3_1_102_1","first-page":"1673","volume":"55","author":"PARKER","year":"1998","unstructured":"PARKER WB, ALLEN PW, SHADDIX S et al.: Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. (1998) 55:1673-1681.","journal-title":"Biochem."},{"key":"e_1_3_1_103_1","first-page":"233","volume":"1","author":"SORSCHER","year":"1994","unstructured":"SORSCHER EJ, PENG S, BEBOK Z, ALLAN PW, BENNETT LL Jr, PARKER WB: Tumor cell bystander killing in colonic carcinoma utilizing the Eschericiha coli DeoD gene to generate toxic purines. Gene Ther. (1994) 1:233-238.","journal-title":"Gene Ther"},{"key":"e_1_3_1_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.08.017"},{"key":"e_1_3_1_105_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26749"},{"key":"e_1_3_1_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990230206"},{"key":"e_1_3_1_107_1","first-page":"103","volume":"6","author":"DOWNING","year":"2001","unstructured":"DOWNING SR, JACKSON P, RUSSELL PJ: Mutations within the tumor suppressor gene p53 are confined to a late event in prostate cancer progression: a review of the evidence. Urol. Oncol. (2001) 6:103-110.","journal-title":"Urol."},{"key":"e_1_3_1_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700451"},{"key":"e_1_3_1_109_1","first-page":"43","volume":"6","author":"MARTINIELLO-WILKS","year":"2004","unstructured":"MARTINIELLO-WILKS R, DANE A, VOEKS DJ, JEYAKUMAR G, WANG XY, RUSSELL PJ: Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J. Gene Med. (2004) 6(1):43-54.","journal-title":"J."},{"key":"e_1_3_1_110_1","first-page":"1343","volume":"6","author":"MARTINIELLO-WILKS","year":"2004","unstructured":"MARTINIELLO-WILKS R, WANG XY, VOEKS DJ et al.: Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J. Gene Med. (2004) 6(12):1343-1357.","journal-title":"J."},{"key":"e_1_3_1_111_1","first-page":"1173","volume":"10","author":"BENNETT","year":"2003","unstructured":"BENNETT EM, ANAND R, ALLAN PW et al.: Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase\/prodrug system. Chem. Biol. (2003) 10(12):1173-1181.","journal-title":"Chem."},{"key":"e_1_3_1_112_1","first-page":"461","volume":"14","author":"GROVE","year":"1999","unstructured":"GROVE JI, SEARLE PF, WEEDON S, GREEN NK, McNEISH IA, KERR DJ: Virus-directed enzyme prodrug therapy using CB1954. Anti-Cancer Drug Des. (1999) 14:461-472.","journal-title":"Anti-Cancer"},{"key":"e_1_3_1_113_1","first-page":"233","volume":"3","author":"DJEHA","year":"2001","unstructured":"DJEHA AH, THOMSON TA, LEUNG H et al.: Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol. Ther. (2001) 3(2):233-240.","journal-title":"Mol."},{"key":"e_1_3_1_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601612"},{"key":"e_1_3_1_115_1","first-page":"247","volume":"55","author":"LIPINSKI","year":"2006","unstructured":"LIPINSKI KS, PELECH S, MOUNTAIN A et al.: Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. Cancer Immunol. Immunother. (2006) 55(3):247-254.","journal-title":"Cancer"},{"key":"e_1_3_1_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700807"},{"key":"e_1_3_1_117_1","first-page":"104","volume":"104","author":"GREEN","year":"2003","unstructured":"GREEN NK, McNEISH IA, DOSHI R: Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int. J. Cancer (2003) 104(1):104-112.","journal-title":"Int."},{"key":"e_1_3_1_118_1","first-page":"822","volume":"311","author":"BENOUCHAN","year":"2003","unstructured":"BENOUCHAN M, NASCIMENTO FD, SEBBAH-LOURIKI M et al.: Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery. Biochem. Biophys. Res. Commun. (2003) 311(4):822-828.","journal-title":"Biochem."},{"key":"e_1_3_1_119_1","first-page":"811","volume":"31","author":"SEARLE","year":"2004","unstructured":"SEARLE PF, CHEN MJ, HU L et al.: Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin. Exp. Pharmacol. Physiol. (2004) 31(11):811-816.","journal-title":"Clin."},{"key":"e_1_3_1_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2005.07.021"},{"key":"e_1_3_1_121_1","first-page":"3624","volume":"43","author":"PARKINSON","year":"2000","unstructured":"PARKINSON GN, SKELLY JV, NEIDLE S: Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J. Med.Chem. (2000) 43(20):3624-3631.","journal-title":"J."},{"key":"e_1_3_1_122_1","author":"ROY","year":"2005","unstructured":"ROY P, WAXMAN DJ: Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol. In Vitro (2005) (In Press).","journal-title":"Toxicol."},{"key":"e_1_3_1_123_1","first-page":"611","volume":"37","author":"ZHANG","year":"2005","unstructured":"ZHANG J, TIAN Q, YUNG CHAN S et al.: Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. (2005) 37(4):611-703.","journal-title":"Drug"},{"key":"e_1_3_1_124_1","first-page":"857","volume":"2","author":"KAN","year":"2002","unstructured":"KAN O, KINGSMAN S, NAYLOR S: Cytochrome P450-based cancer gene therapy: current status. Expert Opin. Biol. Ther. (2002) 2(8):857-868.","journal-title":"Expert"},{"key":"e_1_3_1_125_1","first-page":"944","volume":"89","author":"PALMER","year":"2003","unstructured":"PALMER DH, MILNER AE, KERR DJ, YOUNG LS: Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase\/CB1954, and identification of synergism with 5-fluorouracil. Br. J. Cancer (2003) 89(5):944-950.","journal-title":"Br."},{"key":"e_1_3_1_126_1","first-page":"851","volume":"7","author":"McERLANE","year":"2005","unstructured":"McERLANE V, YAKKUNDI A, McCARTHY HO et al.: A cytochrome P450 2B6 mediated gene theray strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J. Gene Med. (2005) 7(7):851-859.","journal-title":"J."},{"key":"e_1_3_1_127_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301702"},{"key":"e_1_3_1_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2698"},{"key":"e_1_3_1_129_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900189"},{"key":"e_1_3_1_130_1","first-page":"1520","volume":"58","author":"TEH","year":"2004","unstructured":"TEH BS, AYALA G, AGUILAR L et al.: Phase I \u2013 II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(5):1520-1529.","journal-title":"Int."},{"key":"e_1_3_1_131_1","first-page":"347","volume":"13","author":"BARTON","year":"2006","unstructured":"BARTON KN, PAIELLI D, ZHANG Y et al.: Second generation replication-competent oncoloytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. (2006) 13(2):347-356.","journal-title":"Mol."},{"key":"e_1_3_1_132_1","author":"KHATRI","unstructured":"KHATRI A, ZHANG B, DOHERTY E et al.: Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against prostate-cancer in C57BL\/6 mice. J. Gene Med. (Under Revision).","journal-title":"J."},{"key":"e_1_3_1_133_1","first-page":"44","volume":"4","author":"NASU","year":"2001","unstructured":"NASU Y, BANGMA CH, HULL GW et al.: Combination gene therapy with adenoviral vector-mediated HSV-tk + GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prost. Dis. (2001) 4(1):44-55.","journal-title":"Prostate"},{"key":"e_1_3_1_134_1","first-page":"562","volume":"59","author":"SATOH","year":"2004","unstructured":"SATOH T, TEH BS, TIMME TL et al.: Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(2):562-571.","journal-title":"Int."},{"key":"e_1_3_1_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.11.009"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.15.8.947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:07:43Z","timestamp":1770937663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.15.8.947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,21]]},"references-count":133,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1517\/13543784.15.8.947"],"URL":"https:\/\/doi.org\/10.1517\/13543784.15.8.947","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,21]]}}}